About the Company
Boston Scientific Corporation (BSC), is an American biotechnology and biomedical engineering firm and multinational manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology. Known for the development of the Taxus Stent, a drug-eluting stent which is used to open clogged arteries, the company acquired Cameron Health in June 2012 and began to offer a minimally invasive implantable cardioverter-defibrillator (ICD) called the EMBLEM subcutaneous implantable defibrillator (S-ICD). Over the last 20 years, Boston Scientific has had some high-profile patent infringement cases. It has made extensive payouts, including $1.725 billion to Johnson & Johnson, $85 million to Nevro and $42 million to TissueGen. BSC is headquartered in Marlborough, Massachusetts and incorporated in Delaware.
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & Apparatus
Employees
45000
Exchange
NYSE
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on BOSTON SCIENTIFIC CORP
Jefferies Reiterates a Buy Rating on Boston Scientific Corporation (BSX), Sets a $130 PT
Boston Scientific Corporation (NYSE:BSX) is one of the best stocks to invest in for beginners. In a report released on August ...
FDA Monitors Safety Issue with Boston Scientific Defibrillator Leads
Boston Scientific Corporation (NYSE:BSX) is one of the best high-volume stocks to invest in. On August 6, the FDA announced ...
Boston Scientific Reports 16 Deaths Linked To Defibrillator Lead Issue
The FDA is reviewing Boston Scientific's defibrillator leads after reports of rising shock impedance and 16 related deaths.
Boston Scientific updates instructions of devices linked to 17 deaths
The update covers devices used in procedures to implant the company’s Watchman heart device.
Boston Scientific Corp Is Expensive But Worth It (NYSE:BSX)
Company Highlights (Boston Scientific Corp) Tailwinds to Higher Share Price BCC Research claims the global medical device market is growing at a CAGR rate of 9.8% and will reach $1.3T by 2029.
Solid Company Fundamentals Lifted Boston Scientific Corporation (BSX ...
On February 18, 2025, Boston Scientific Corporation (NYSE:BSX) stock closed at $105.35 per share with a market capitalization of $155.268 billion.
Warning issued by FDA for 2 heart devices made by Boston Scientific. What to know
While neither warning is classified as a recall, the FDA has provided additional information for the two products. Boston Scientific told customers that its Endotak Reliance defibrillation leads with ...
Boston Scientific survey reveals weight loss struggles among women, launches Endura procedures
Boston Scientific has launched Endura Weight Loss Solutions, alongside survey findings showing that many U.S. women are ...
Boston Scientific Corp. Takes Over #24 Spot From NVIDIA Corp
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Boston Scientific Corp. (Symbol: BSX) has taken over the #24 spot from NVIDIA Corp ...
Truist Boosts Boston Scientific (BSX) Price Target After Strong Quarter
Boston Scientific Corporation (NYSE:BSX) ranks among the best medical stocks to buy according to analysts. On July 25, Truist ...
Boston Scientific earns Medicare reimbursement for Agent drug-coated balloon
Boston Scientific (NYSE: BSX) announced today that CMS granted reimbursement for its Agent drug-coated balloon (DCB).
Boston Scientific Corporation (BSX) Hit a 52 Week High, Can ... - Nasdaq
For the current fiscal year, Boston Scientific is expected to post earnings of $2.40 per share on $16.26 billion in revenues. This represents a 17.07% change in EPS on a 14.22% change in revenues.
Similar Companies
Loading the latest forecasts...